ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ SỚM UNG THƯ VÒM MŨI HỌNG GIAI ĐOẠN II-IVA BẰNG HÓA XẠ TRỊ ĐỒNG THỜI TẠI BỆNH VIỆN UNG BƯỚU THÀNH PHỐ CẦN THƠ NĂM 2024-2026

Abstract

 Background: Nasopharyngeal carcinoma (NPC) is a malignancy primarily characterized by representing a major burden among head and neck cancers. Although Vietnam is recorded as a country with a high incidence rate, the reality of disease detection remains limited. Statistical reports indicate that the majority of patients are only diagnosed and treated when the tumor has exceeded the localized stage, progressing to a locally or regionally advanced state. For patients in stages II–IVA, concurrent chemoradiotherapy is currently considered the standard regimen due to its capacity to optimize local disease control while significantly reducing the risk of distant metastasis. Objectives: To describe the clinical characteristics and evaluate the early treatment outcomes of concurrent chemoradiotherapy for stage II–IVA nasopharyngeal carcinoma at Can Tho Oncology Hospital. Materials and methods: A total of 30 patients diagnosed with stage II–IVA nasopharyngeal carcinoma who received concurrent chemoradiotherapy at Can Tho Oncology Hospital from 2024 to 2026 were enrolled. This was a cross-sectional descriptive study with clinical intervention, without a control group, utilizing convenience sampling. Results: Clinical characteristics upon admission were predominantly cervical lymphadenopathy (90%), tinnitus (66.7%), and nasal congestion (50%). The overall complete response (CR) rate was 83.3%; the complete response rates at the primary tumor site and cervical lymph nodes were 93.3% and 92.6%, respectively. The majority of acute treatment-related toxicities were observed at grade 2. Conclusion: Concurrent chemoradiotherapy is a highly effective and feasible treatment strategy for stage II–IVA nasopharyngeal carcinoma, demonstrated by excellent tumor and nodal control, with acute toxicities within an acceptable tolerance level.